The results offer some of the first glimpses into real-world findings of the Janus kinase inhibitor in patients with ...

Infection was a leading cause of death in lower-risk myelodysplastic syndromes (MDS), highlighting the need for vigilant ...

Keros' cash and cash equivalents as of March 31, 2025 was $720.5 million compared to $559.9 million as of December 31, 2024.

DelveInsight's " Aplastic Anemia Market Insights, Epidemiology, and Market Forecast- 2034" report delivers an in-depth ...

Panelists discuss how Janus kinase (JAK) inhibitors like pacritinib offer crucial treatment options for myelofibrosis patients with severe thrombocytopenia (platelet counts <50,000 ), highlighting its ...

According to Future Market Insights, myelofibrosis (mf) treatment market is expected to grow at a CAGR of 5.5% between 2023 and 2033, reaching USD 1,280 Million by 2033. The market is expected to ...

In recent years, there has been a growing trend of an aging patient population and an increasing prevalence of age-associated diseases, underscoring the need for advancing research into the biological ...

However, with age, HSCs become biased toward differentiating into myeloid cells and platelets rather than ... and can contribute to anemia, immune deficiencies, and even blood cancers.

Rubraca treatment may reduce the level of certain blood cells. Thrombocytopenia and anemia were the most commonly reported blood cell-related side effects in Rubraca’s studies. With ...

Hematopoietic stem cells (HSCs) can differentiate into any blood cell. However, as HSCs age, they are more likely to ...

Final data from the phase 3 ALCYONE trial support frontline use of daratumumab-based therapy for patients with ...

Pope Francis's stay at the Gemelli Polyclinic began with hospitalization after the exacerbation of bronchitis and the onset of a respiratory tract infection. The initial medical ...